Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,540.00    9.00 (0.59%)
Bid:
1,535.00
Ask:
1,536.00
Spread: 1.00 (0.065%)
Market Cap: £3.24b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

LTIP Awards

30 Apr 2008 15:22

Hikma Pharmaceuticals Plc30 April 2008 Hikma Pharmaceuticals PLC - LTIP Awards LONDON, 30 April 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)announces that the Remuneration Committee has made the following nil-cost awardsunder the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the "LTIP")to Directors and Persons Discharging Managerial Responsibility ("PDMRs") of theCompany. Awards under the LTIP were made on 29 April 2008 at a price of £4.64 perordinary share as follows:- Name of Director/PDMR Number of LTIP SharesSaid Darwazah 90,000Mazen Darwazah 54,000Bassam Kanaan 54,000Taghreed Al-Shunnar 54,000Majda Labadi 54,000Nabil Rizk 54,000 The shares subject to the LTIP awards will only be released to the participantsin three years time, subject to their continued employment and the satisfactionof the comparative Total Shareholder Return ("TSR") performance target.Participants will only receive the full benefit of their share incentives if TSRperformance against the Comparator Group is at least at the upper quartile. - ENDS -Enquiries: Hikma Pharmaceuticals PLCHenry Knowles +44 20 7399 2760Company Secretary Susan Ringdal +44 20 7399 2760Investor Relations Director About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and"Generics". Hikma's operations are based principally in the Middle East andNorth Africa ("MENA") region, where it is a market leader and sells across 17countries, the United States and Europe. In 2007, the Group achieved revenuesof $449 million (2006 $317 million) and profit attributable to shareholders was$63 million (2006 $55 million). For news and other information, please visitwww.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th May 20225:47 pmRNSTransaction in Own Shares
5th May 20227:00 amRNSHikma updates Generics guidance for 2022
4th May 20225:58 pmRNSTransaction in Own Shares
3rd May 20226:08 pmRNSTransaction in Own Shares
29th Apr 20225:29 pmRNSTransaction in Own Shares
29th Apr 20225:05 pmRNSCorrection statement re Opiant
29th Apr 20227:15 amRNSTrading Statement
28th Apr 20226:05 pmRNSTransaction in Own Shares
27th Apr 20226:17 pmRNSTransaction in Own Shares
27th Apr 20227:00 amRNSTransaction in Own Shares
25th Apr 20226:04 pmRNSTransaction in Own Shares
25th Apr 20223:42 pmRNSResult of AGM
25th Apr 20227:00 amRNSNotice of GM
22nd Apr 20226:15 pmRNSTransaction in Own Shares
21st Apr 20226:06 pmRNSTransaction in Own Shares
21st Apr 20222:15 pmRNSAcquisition
20th Apr 20225:59 pmRNSTransaction in Own Shares
20th Apr 20227:00 amRNSFTC preliminary approval for Custopharm
19th Apr 20225:49 pmRNSTransaction in Own Shares
14th Apr 20225:35 pmRNSTransaction in Own Shares
13th Apr 20225:19 pmRNSTransaction in Own Shares
12th Apr 20225:55 pmRNSTransaction in Own Shares
12th Apr 20225:49 pmRNSDirector/PDMR Shareholding
11th Apr 20226:09 pmRNSTransaction in Own Shares
11th Apr 20227:00 amRNSShare Buyback Programme
8th Apr 20225:16 pmRNSTransaction in Own Shares
7th Apr 20225:53 pmRNSTransaction in Own Shares
5th Apr 20225:59 pmRNSTransaction in Own Shares
4th Apr 20226:09 pmRNSTransaction in Own Shares
1st Apr 20226:13 pmRNSTransaction in Own Shares
1st Apr 20225:46 pmRNSBlock listing Interim Review
31st Mar 20226:09 pmRNSTransaction in Own Shares
30th Mar 20225:57 pmRNSTransaction in Own Shares
30th Mar 202212:54 pmRNSTransaction in Own Shares
28th Mar 20226:09 pmRNSTransaction in Own Shares
25th Mar 20225:55 pmRNSTransaction in Own Shares
24th Mar 20226:03 pmRNSTransaction in Own Shares
23rd Mar 20225:08 pmRNSTransaction in Own Shares
22nd Mar 20226:03 pmRNSTransaction in Own Shares
21st Mar 20225:58 pmRNSTransaction in Own Shares
18th Mar 20226:32 pmRNSTransaction in Own Shares
17th Mar 20226:03 pmRNSTransaction in Own Shares
17th Mar 202210:00 amRNSAnnual Financial Report
16th Mar 20225:48 pmRNSTransaction in Own Shares
15th Mar 20225:51 pmRNSTransaction in Own Shares
15th Mar 202210:58 amRNSDirector/PDMR Shareholding
14th Mar 20226:23 pmRNSTransaction in Own Shares
11th Mar 20226:11 pmRNSTransaction in Own Shares
10th Mar 20225:48 pmRNSTransaction in Own Shares
9th Mar 20225:53 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.